Patients and tumor characteristics are provided inside Second Stand S1. When it comes to review cohort, there was no significant difference relating to the bevacizumab and chemotherapy-alone teams for your major available clinicobiological traits, with the exception of anti-EGFR treatment, that has been with greater regularity received by simply patients from the bevacizumab class (53 as opposed t